Last CNY5.88 CNY
Change Today 0.00 / 0.00%
Volume 5.1M
As of 3:05 AM 04/18/14 All times are local (Market data is delayed by at least 15 minutes).

harbin pharmaceutical grp-a (600664) Snapshot

Open
CNY5.87
Previous Close
CNY5.88
Day High
CNY5.90
Day Low
CNY5.83
52 Week High
05/15/13 - CNY7.87
52 Week Low
02/7/14 - CNY5.57
Market Cap
11.3B
Average Volume 10 Days
8.5M
EPS TTM
CNY0.25
Shares Outstanding
1.9B
EX-Date
08/1/13
P/E TM
23.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for HARBIN PHARMACEUTICAL GRP-A (600664)

Related News

No related news articles were found.

harbin pharmaceutical grp-a (600664) Related Businessweek News

No Related Businessweek News Found

harbin pharmaceutical grp-a (600664) Details

Harbin Pharmaceutical Group Co., Ltd. engages in the research, manufacture, and trading of pharmaceutical products in China. It provides 30 antibiotics, including penicillins and cephalosporin; and ampicillin sodium, cefotaxime sodium powder, cefazolin sodium injectable powder, and ceftriaxone sodium powder. The company also offers chemical medicine products comprising therapeutic drugs for cardiovascular, cerebrovascular, and digestive system diseases; vitamins, steroids, and anti-infection drugs; and medicines in various dosage forms, such as small dose injections, injectable powders, oral liquids, tablets, and capsules. In addition, it provides approximately 110 kinds of over the counter drugs and health food products, which include New Gaizhonggai high calcium, Hutong children’s granules, Puxue oral liquids, and Weixiao Lactobacilli tablet in infusion solution, oral liquid, syrup, tablet, capsule, and granules dosage forms. Further, the company offers bioengineering products consisting of human interferon a2b for injection under the Lifenneng brand; erythropoietin for injection under the Xuedasheng brand name; granulocyte macrophage colony for injection under the brand name of Liyajin; granulocyte colony-stimulating factor for injection under the Liyaer brand name; and interferon a2b ointment under the brand name of Liyamei. Additionally, it provides animal vaccines and health products; and medicine logistic services, as well as operates retail chain pharmacies. The company exports its products primarily to Europe, Asia, Africa, and North and Central America. Harbin Pharmaceutical Group Co., Ltd. is based in Harbin, China.

harbin pharmaceutical grp-a (600664) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

harbin pharmaceutical grp-a (600664) Key Developments

Harbin Pharmaceutical Group Co., Ltd. to Report Q3, 2013 Results on Oct 31, 2013

Harbin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2013 results on Oct 31, 2013

Harbin Pharmaceutical Group Co., Ltd., Board Meeting, Jul 26, 2013

Harbin Pharmaceutical Group Co., Ltd., Board Meeting, Jul 26, 2013. Agenda: To discuss and approve the proposal of construction project of Pharmaceutical Academy of Harbin Pharmaceutical Group; and to consider the proposal of appointing Sha Mei Deputy General Manager.

Harbin Pharmaceutical Group Co., Ltd. to Report First Half, 2013 Results on Aug 31, 2013

Harbin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2013 results on Aug 31, 2013

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600664:CH CNY5.88 CNY 0.00

600664 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Kirin Holdings Co Ltd ¥1,410 JPY +5.00
Roche Holding AG SFr.254.90 CHF +0.70
View Industry Companies
 

Industry Analysis

600664

Industry Average

Valuation 600664 Industry Range
Price/Earnings 23.4x
Price/Sales 0.6x
Price/Book 1.3x
Price/Cash Flow 23.3x
TEV/Sales 0.4x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HARBIN PHARMACEUTICAL GRP-A, please visit www.hayao.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.